Human RCTPubMed ID: 35015037·2022

Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (STEP 8)

Rubino DM, Greenway FL, Khalid U, et al.

JAMA, 2022 · n = 338

Key finding

Semaglutide demonstrated 2.5x greater weight loss than liraglutide in direct comparison, establishing it as the more effective GLP-1 RA for weight management.

Summary

Head-to-head trial showing semaglutide 2.4mg weekly produced 15.8% weight loss versus 6.4% with liraglutide 3.0mg daily.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

SemaglutideL5

An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management.

More research on Semaglutide

Semaglutide and Cardiovascular Outcomes in Patients with Overweight or Obesity (SELECT)

New England Journal of Medicine · 2023 · Human RCT

Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity (STEP-HFpEF)

New England Journal of Medicine · 2023 · Human RCT

Two-Year Effects of Semaglutide in Adults with Overweight or Obesity (STEP 5)

Nature Medicine · 2022 · Human RCT

STEP 3: Semaglutide for Weight Management in Severe Obesity

New England Journal of Medicine · 2022 · Human RCT

Semaglutide Effects on Heart Failure Symptoms in HFmrEF

JAMA Cardiology · 2022 · Human Pilot